Pharma Layoffs June 2026: The 39,000-Job Wave Hitting Biotech and Big Pharma Now

If you work in pharmaceutical or biotech, June 2026 is not the month to coast. WARN Act notices are expiring, headcount reductions announced months ago are becoming real terminations, and six major pharma companies alone are on track to eliminate over 39,000 jobs before the year ends.

This isn't speculation. The filings are public, the timelines are set, and the first wave of June cuts is already landing. Here's the full picture — who's cutting, when, and what pharma professionals can do right now.

The Scale: 39,000 Jobs from Just Six Companies

The pharmaceutical sector is in the middle of its deepest restructuring cycle since the patent cliff era of the early 2010s. According to BioSpace's layoff tracker, six major pharma companies alone could eliminate more than 39,000 positions through 2026 — and that figure doesn't include the dozens of smaller biotech firms cutting even larger percentages of their workforces.

The headline numbers:

• Novo Nordisk: ~9,000 employees cut globally by end of 2026, despite massive GLP-1 drug revenues, as the company restructures manufacturing and R&D operations
• Bayer: headcount has dropped by 12,492 employees between Q2 2023 and Q2 2025, with additional cuts expected through its "Dynamic Shared Ownership" restructuring program
• Bristol-Myers Squibb: 1,000+ total layoffs across 2025–2026 as part of a $2 billion cost-cutting initiative targeting completion by 2027
• Merck: $3 billion cost-cutting program underway, with 204 roles at the Rahway, NJ campus alone and additional cuts extending through Q3
• Novartis: ~400 employees in U.S. and German operations, with specific WARN notices filed for East Hanover, NJ effective through November
• Gilead Sciences: 192 employees being cut following its $7.8 billion Arcellx acquisition integration

That's before you factor in mid-size and small biotech companies that have been cutting even more aggressively.

The June WARN Deadlines You Should Know

WARN Act notices require employers to give 60 days' advance notice before mass layoffs — which means notices filed in March and April are materializing as actual terminations right now.

Here's what's hitting in June specifically:

Novartis (East Hanover, NJ): Two separate WARN-covered layoff waves, with the first batch of 114 employees effective June 26, 2026, followed by a second group of 60 employees running from July 24 through November 20. These cuts are concentrated in Novartis's biomedical research arm — basic science and early discovery roles are bearing the brunt.

Merck (Rahway, NJ): Merck continues extending its New Jersey restructuring, with 88 additional employees at the Rahway campus notified in the latest filing. The cuts span vaccine manufacturing and supporting roles, part of the broader $3 billion efficiency program.

Bristol-Myers Squibb: BMS filed a WARN notice for 206 jobs with effective dates spanning July through December, with pre-layoff notices making June the active communication window. The BMS program targets manufacturing, admin, and some R&D support roles across New Jersey and other major facilities.

UnitedHealth Group / Optum: Several Optum divisions filed WARN notices covering early-to-mid 2026, with Optum Care alone planning to cut 390 employees. The healthcare-pharma overlap here hits PBM operations, specialty pharmacy, and health services analytics.

If you received a WARN notice or are in an at-risk department, you have more rights than most people realize. Read our breakdown of WARN Act employee rights before your last day.

The Smallest Cuts Are Sometimes the Most Alarming

The large-company numbers above are sobering, but the most severe restructurings are happening at smaller biotechs where cuts represent the majority of the workforce.

Fulcrum Therapeutics announced on June 4, 2026, that it is cutting 85% of its staff — effectively a near-total wind-down — after scrapping its only clinical-stage program following negative FDA feedback on FTX-6058 for sickle cell disease. When a single program failure can vaporize most of a company's headcount overnight, it illustrates the existential risk that clinical-stage biotech employees carry.

This pattern has been consistent across 2026: small and mid-cap biotechs with concentrated pipeline risk are collapsing on failed Phase 2 and Phase 3 readouts, while large pharmas use restructuring as cover for multi-year cost reduction programs that were planned long before any specific "efficiency" narrative.

Why Pharma Is Cutting Now — Even as Some Products Boom

The apparent paradox of 2026 pharma layoffs is that some of these companies are enormously profitable. Novo Nordisk's GLP-1 drugs (Ozempic, Wegovy) generate tens of billions annually. Merck's Keytruda alone cleared $20+ billion in 2025 revenue.

So why the cuts? Three structural forces are driving layoffs regardless of top-line performance:

1. R&D consolidation after acquisition-driven portfolio bloat. Post-M&A integration has triggered duplicate function elimination at nearly every major acquirer. Pfizer's post-COVID spending spree, BMS's Celgene absorption, Gilead's Arcellx deal — each acquisition creates a redundancy elimination cycle 12–24 months later.

2. AI-driven automation in clinical, regulatory, and commercial functions. Regulatory submission drafting, pharmacovigilance signal detection, and some medical writing roles are being automated using large language models. According to IntuitionLabs' pharma-CRO layoff analysis, CRO (contract research organization) positions in data management, biostatistics, and medical monitoring are increasingly first to be restructured as AI tools reduce the headcount required per trial.

3. Cost-cutting ahead of patent cliffs. Multiple blockbusters lose exclusivity between 2026 and 2030. Companies are cutting now to build cost structures that can survive revenue declines from generics competition, regardless of what AI actually delivers.

Which Pharma Roles Are Most at Risk in 2026

Not all functions are equally exposed. Based on current layoff patterns across the sector:

Highest risk:

• Medical writing and regulatory affairs document preparation (AI automation)
• Commercial operations, sales operations, and field force analytics
• Early-stage R&D (pre-clinical and discovery) at companies doing portfolio prioritization
• Business development and licensing support roles
• Duplicated G&A functions post-acquisition (finance, HR, IT)

Moderate risk:

• Clinical project managers and CRAs (insourcing + AI documentation tools)
• Pharmacovigilance coordinators
• Market access and HEOR (health economics), where team sizes are being trimmed

Lower risk (relatively):

• Regulatory affairs leads with NDA/BLA submission experience
• Clinical data scientists and biostatisticians who can use AI tools
• Manufacturing and quality assurance (especially for biologics and gene therapy)
• Medical science liaisons with active key account relationships
• Specialty sales reps with strong regional relationships in oncology and rare disease

What to Do If You Work in Pharma Right Now

The window before a layoff is always more valuable than the time after. Here's how to use it:

Audit your role's automation exposure. If more than 30% of your day involves tasks that can be described as document creation, data formatting, or templated reporting — and you're at a company with an active cost-reduction program — start treating your position as at risk.

Document your revenue/pipeline impact. In pharma, the people who survive layoffs are those who can draw a direct line from their work to a regulatory milestone, a commercial launch, or a revenue-generating asset. Rebuild your performance narrative around those connections before you need it.

Secure your severance terms before signing anything. Pharma severance packages are often negotiable, especially for professionals with specialized regulatory knowledge. Companies don't advertise this. Read our severance negotiation guide before you accept any package.

Get COBRA or marketplace coverage sorted immediately. Pharma roles often come with premium employer-subsidized health coverage. Losing it is a significant financial shock. Understand your health insurance options after layoff before the termination date, not after.

Start your network activation now. Pharma is a small industry where referrals move faster than job boards. If you've been passive on LinkedIn for years, a layoff is not the time to build relationships from zero. Start now.

Key Takeaways

• Six major pharmaceutical companies are on track to eliminate 39,000+ jobs in 2026, led by Novo Nordisk (9,000), Bayer (12,000+), and Bristol-Myers Squibb (1,000+)
• June 2026 is a high-activity window for WARN Act notice expirations, with Novartis, Merck, and BMS cuts becoming effective in late June and July
• Smaller biotechs are cutting even more severely — Fulcrum Therapeutics eliminated 85% of its workforce in early June after a failed clinical program
• The drivers are structural: post-acquisition redundancy, AI automation of clinical and commercial functions, and pre-patent-cliff cost repositioning
• Pharma roles in regulatory document production, commercial analytics, and early R&D are most exposed; manufacturing, biostatistics, and MSL roles have more cushion

What to Do in the Next 72 Hours

If you're in pharma and worried about your position, don't wait for an email. Take our layoff risk assessment — it scores your specific role, company health signals, and industry exposure so you know exactly where you stand. Then, if the risk is real, use the first 72 hours action plan to move before the market gets crowded with your former colleagues.

The pharma job market will recover. It always does. But the professionals who navigate this cycle best are the ones who acted when the data was clear — not when the calendar invite arrived.